Alirocumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1024 publications

Correction.

Correction.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Expanded indication for PCSK9 inhibitors.

Expanded indication for PCSK9 inhibitors.

Journal: The Medical letter on drugs and therapeutics

Published: December 15, 2025

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.

Journal: Circulation

Published: December 01, 2025

PCSK9 Inhibition Protects Against Myocardial Ischemia-Reperfusion Injury in Type 2 Diabetes Rats Via Suppressing Inflammation and Apoptosis.

PCSK9 Inhibition Protects Against Myocardial Ischemia-Reperfusion Injury in Type 2 Diabetes Rats Via Suppressing Inflammation and Apoptosis.

Journal: Anatolian journal of cardiology

Published: November 17, 2025

Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.

Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.

Journal: Circulation

Published: November 10, 2025

Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.

Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.

Journal: Circulation

Published: November 10, 2025

Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.

Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.

Journal: Journal of medical economics

Published: October 20, 2025

Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.

Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.

Journal: Journal of medical economics

Published: October 20, 2025

Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction.

Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction.

Journal: Journal of the American Heart Association

Published: October 09, 2025

Prescribing Patterns of Evolocumab and Alirocumab in Patients With Familial Hypercholesterolemia: A Cross-Sectional Study Using the National Ambulatory Medical Care Survey, 2018-2019.

Prescribing Patterns of Evolocumab and Alirocumab in Patients With Familial Hypercholesterolemia: A Cross-Sectional Study Using the National Ambulatory Medical Care Survey, 2018-2019.

Journal: Cureus

Published: September 30, 2025

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: September 25, 2025

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective.

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective.

Journal: Frontiers in pharmacology

Published: September 19, 2025

Showing 1-12 of 1,024

Last Updated: 02/24/2026